KBY Biotech Indexv0.0.34
Search
← Pipeline|PFE-8662

PFE-8662

NDA/BLA
By Pfizer
Source: Trial-derived·Trials: 1
Modality
ADC
MOA
GLP-1ag
Target
CD19
Pathway
Proteasome
NBMigraineAsthma
Development Pipeline
Preclinical
~Jan 2012
→ ~Apr 2013
Phase 1
~Jul 2013
→ ~Oct 2014
Phase 2
~Jan 2015
→ ~Apr 2016
Phase 3
~Jul 2016
→ ~Oct 2017
NDA/BLA
Jan 2018
NDA/BLACurrent
NCT05781362
1,109 pts·NB
2018-01→TBD·Not yet recruiting
1,109 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
2018
NDA/BLA
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05781362NDA/BLANBNot yet recr...1109EDSS
Competitors (10)
DrugCompanyPhaseTargetMOA
NVS-6974NovartisPreclinicalCD19HPK1i
VoxarasimodMerck & CoPhase 1/2CD19AuroraAi
NVO-7840Novo NordiskPhase 2/3B7-H3GLP-1ag
MRN-7601ModernaPhase 2IL-13GLP-1ag
ARG-1250ArgenxPhase 2C5GLP-1ag
ILM-5680IlluminaPhase 2BETGLP-1ag
TirarelsinTG TherapeuticsNDA/BLACD19IL-17i
CRS-184CRISPR TherapeuticsPhase 1/2AHRGLP-1ag
PolazanubrutinibTango TherPhase 1IL-17AGLP-1ag
VYG-2926VoyagerNDA/BLACD19PI3Ki